Display options
Cite
Weiss SA, Sznol M. Resistance mechanisms to checkpoint inhibitors. Curr Opin Immunol. 2021;69:47-55doi: 10.1016/j.coi.2021.02.001.
Weiss, S. A., & Sznol, M. (2021). Resistance mechanisms to checkpoint inhibitors. Current opinion in immunology, 6947-55. https://doi.org/10.1016/j.coi.2021.02.001
Weiss, Sarah A, and Sznol, Mario. "Resistance mechanisms to checkpoint inhibitors." Current opinion in immunology vol. 69 (2021): 47-55. doi: https://doi.org/10.1016/j.coi.2021.02.001
Weiss SA, Sznol M. Resistance mechanisms to checkpoint inhibitors. Curr Opin Immunol. 2021 Apr;69:47-55. doi: 10.1016/j.coi.2021.02.001. Epub 2021 Mar 03. PMID: 33676271.
Copy Download .nbib Format: NLM
Share it on

Curr Opin Immunol. 2021 Apr;69:47-55. doi: 10.1016/j.coi.2021.02.001. Epub 2021 Mar 03.

Resistance mechanisms to checkpoint inhibitors.

Current opinion in immunology

Sarah A Weiss, Mario Sznol

Affiliations

  1. Yale University School of Medicine, Department of Medicine (Section of Medical Oncology), 333 Cedar St., P.O. Box 208032, New Haven, CT 06520, United States. Electronic address: [email protected].
  2. Yale University School of Medicine, Department of Medicine (Section of Medical Oncology), 333 Cedar St., P.O. Box 208032, New Haven, CT 06520, United States.

PMID: 33676271 DOI: 10.1016/j.coi.2021.02.001

Abstract

Although multiple immune checkpoint inhibitors (ICI) have been identified and tested in the clinic, antibodies blocking the PD-1/PD-L1 axis have produced the greatest impact on cancer treatment. Many potential mechanisms of treatment failure have been proposed from pre-clinical animal and human translational studies. Pre-clinical studies and clinical trials are underway to better understand how resistance arises and to develop strategies that can circumvent these resistance mechanisms and sensitize patients to anti-PD1/PD-L1 to improve clinical outcomes.

Copyright © 2021. Published by Elsevier Ltd.

Publication Types